These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38432446)

  • 1. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
    Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
    Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
    Zhu M; Bai L; Liu X; Peng S; Xie Y; Bai H; Yu H; Wang X; Yuan P; Ma R; Lin J; Wu L; Huang M; Li Y; Luo Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
    Chen TW; Hung WZ; Chiang SF; Chen WT; Ke TW; Liang JA; Huang CY; Yang PC; Huang KC; Chao KSC
    Cancer Lett; 2022 Sep; 543():215795. PubMed ID: 35718267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.
    Lv Q; Yang H; Wang D; Zhou H; Wang J; Zhang Y; Wu D; Xie Y; Lv Y; Hu L; Wang J
    J Med Chem; 2024 Apr; 67(8):6854-6879. PubMed ID: 38593344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
    Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
    Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
    Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
    Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal Cancer-Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD-L1 Expression in Tumor-Associated Macrophages.
    Yin Y; Liu B; Cao Y; Yao S; Liu Y; Jin G; Qin Y; Chen Y; Cui K; Zhou L; Bian Z; Fei B; Huang S; Huang Z
    Adv Sci (Weinh); 2022 Mar; 9(9):2102620. PubMed ID: 35356153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated macrophages employ immunoediting mechanisms in colorectal tumor progression: Current research in Macrophage repolarization immunotherapy.
    Cheruku S; Rao V; Pandey R; Rao Chamallamudi M; Velayutham R; Kumar N
    Int Immunopharmacol; 2023 Mar; 116():109569. PubMed ID: 36773572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer.
    He S; Song W; Cui S; Li J; Jiang Y; Chen X; Peng L
    Cell Oncol (Dordr); 2023 Dec; 46(6):1731-1746. PubMed ID: 37402945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
    Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
    Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer.
    Min AKT; Mimura K; Nakajima S; Okayama H; Saito K; Sakamoto W; Fujita S; Endo H; Saito M; Saze Z; Momma T; Ohki S; Kono K
    Cancer Immunol Immunother; 2021 Feb; 70(2):289-298. PubMed ID: 32705303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
    Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
    J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.
    Magkouta SF; Vaitsi PC; Pappas AG; Iliopoulou M; Kosti CN; Psarra K; Kalomenidis IT
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
    Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.